Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 384

1.

Peri- and Postpartum Management of Patients With Factor XI Deficiency.

Gerber GF, Klute KA, Chapin J, Bussel J, DeSancho MT.

Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619880262. doi: 10.1177/1076029619880262.

PMID:
31595781
2.

Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia.

Zhang H, Zhang BM, Guo X, Xu L, You X, West RB, Bussel JB, Zehnder JL.

Haematologica. 2019 Jul 11. pii: haematol.2019.226688. doi: 10.3324/haematol.2019.226688. [Epub ahead of print]

3.

Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.

Garabet L, Ghanima W, Hellum M, Sandset PM, Bussel JB, Tran H, Henriksson CE.

Platelets. 2019 Jul 7:1-7. doi: 10.1080/09537104.2019.1639655. [Epub ahead of print]

PMID:
31280643
4.

FAS mutations are an uncommon cause of immune thrombocytopenia in children and adults without additional features of immunodeficiency.

Vandrovcova J, Salzer U, Grimbacher B, Wanders J, Rao K, Thrasher A, Burns S, Gilmore K, Bussel J, Cooper N.

Br J Haematol. 2019 Sep;186(6):e163-e165. doi: 10.1111/bjh.15979. Epub 2019 Jun 6. No abstract available.

PMID:
31172514
5.

Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?

Lucchini E, Zaja F, Bussel J.

Haematologica. 2019 Jun;104(6):1124-1135. doi: 10.3324/haematol.2019.218883. Epub 2019 May 24. Review.

6.

Thrombopoietin receptor agonists: ten years later.

Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB.

Haematologica. 2019 Jun;104(6):1112-1123. doi: 10.3324/haematol.2018.212845. Epub 2019 May 9. Review.

7.

Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia.

Jin JC, Lakkaraja MM, Ferd P, Manotas K, Gabor J, Wissert M, Berkowitz RL, McFarland JG, Bussel JB.

Am J Hematol. 2019 Aug;94(8):E213-E215. doi: 10.1002/ajh.25503. Epub 2019 May 16. No abstract available.

PMID:
31056760
8.

Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia.

Hogan M, Geyer JT, Bussel JB.

Am J Hematol. 2019 Jul;94(7):E196-E198. doi: 10.1002/ajh.25496. Epub 2019 May 3. No abstract available.

PMID:
31012979
9.

Postnatal intervention for the treatment of FNAIT: a systematic review.

Baker JM, Shehata N, Bussel J, Murphy MF, Greinacher A, Bakchoul T, Massey E, Lieberman L, Landry D, Tanael S, Arnold DM, Baidya S, Bertrand G, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Savoia H, Ryan G, Hume H; International Collaboration for Transfusion Medicine Guidelines (ICTMG).

J Perinatol. 2019 Oct;39(10):1329-1339. doi: 10.1038/s41372-019-0360-7. Epub 2019 Apr 10. Review.

PMID:
30971767
10.

Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM.

Am J Hematol. 2019 Jul;94(7):741-750. doi: 10.1002/ajh.25479. Epub 2019 Apr 29.

PMID:
30945320
11.

Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.

Garabet L, Ghanima W, Rangberg A, Teruel-Montoya R, Martinez C, Lozano ML, Nystrand CF, Bussel JB, Sandset PM, Jonassen CM.

Platelets. 2019 Mar 18:1-8. doi: 10.1080/09537104.2019.1585527. [Epub ahead of print]

PMID:
30885035
12.

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.

Tarantino MD, Bussel JB, Blanchette VS, Beam D, Roy J, Despotovic J, Raj A, Carpenter N, Mehta B, Eisen M.

Haematologica. 2019 Mar 7. pii: haematol.2018.202283. doi: 10.3324/haematol.2018.202283. [Epub ahead of print]

13.

Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach.

Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S, Kjaer M, Kjeldsen-Kragh J, Bertrand G, Oepkes D, Baker JM, Hume H, Massey E, Kaplan C, Arnold DM, Baidya S, Ryan G, Savoia H, Landry D, Shehata N; International Collaboration for Transfusion Medicine Guidelines (ICTMG).

Br J Haematol. 2019 May;185(3):549-562. doi: 10.1111/bjh.15813. Epub 2019 Mar 3.

PMID:
30828796
14.

Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.

Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM.

Am J Hematol. 2019 May;94(5):546-553. doi: 10.1002/ajh.25444. Epub 2019 Mar 13.

15.

Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.

Grainger JD, Blanchette VS, Grotzinger KM, Roy A, Bussel JB.

Br J Haematol. 2019 Apr;185(1):102-106. doi: 10.1111/bjh.15732. Epub 2018 Dec 27.

PMID:
30592022
16.

Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review.

Kjaer M, Bertrand G, Bakchoul T, Massey E, Baker JM, Lieberman L, Tanael S, Greinacher A, Murphy MF, Arnold DM, Baidya S, Bussel J, Hume H, Kaplan C, Oepkes D, Ryan G, Savoia H, Shehata N, Kjeldsen-Kragh J; International Collaboration for Transfusion Medicine Guidelines.

Vox Sang. 2019 Jan;114(1):79-94. doi: 10.1111/vox.12725. Epub 2018 Nov 22.

PMID:
30565711
17.

Platelet transfusion practices in immune thrombocytopenia related hospitalizations.

Goel R, Chopra S, Tobian AAR, Ness PM, Frank SM, Cushing M, Vasovic L, Kaicker S, Takemoto C, Josephson CD, Nellis M, Bussel J, Krishnamurti L.

Transfusion. 2019 Jan;59(1):169-176. doi: 10.1111/trf.15069. Epub 2018 Dec 5.

PMID:
30520045
18.

Health Data for Research Through a Nationwide Privacy-Proof System in Belgium: Design and Implementation.

Delvaux N, Aertgeerts B, van Bussel JC, Goderis G, Vaes B, Vermandere M.

JMIR Med Inform. 2018 Nov 19;6(4):e11428. doi: 10.2196/11428.

19.

Health-related quality of life in adult primary immune thrombocytopenia.

Sestøl HG, Trangbæk SM, Bussel JB, Frederiksen H.

Expert Rev Hematol. 2018 Dec;11(12):975-985. doi: 10.1080/17474086.2018.1548930. Epub 2018 Nov 27. Review.

PMID:
30444433
20.

Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.

Khelif A, Saleh MN, Salama A, Portella MDSO, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

Am J Hematol. 2019 Feb;94(2):200-208. doi: 10.1002/ajh.25348. Epub 2018 Nov 29.

Supplemental Content

Loading ...
Support Center